Startseite Increased serum concentrations of soluble ST2 predict mortality after burn injury
Artikel
Lizenziert
Nicht lizenziert Erfordert eine Authentifizierung

Increased serum concentrations of soluble ST2 predict mortality after burn injury

  • Stefan Hacker ORCID logo EMAIL logo , Benjamin Dieplinger , Gregor Werba , Stefanie Nickl , Georg A. Roth , Claus G. Krenn , Thomas Mueller , Hendrik J. Ankersmit und Thomas Haider
Veröffentlicht/Copyright: 27. Juni 2018
Veröffentlichen auch Sie bei De Gruyter Brill
Manuskript einreichen Informationen für Autor*innen
Clinical Chemistry and Laboratory Medicine (CCLM)
Aus der Zeitschrift Clinical Chemistry and Laboratory Medicine (CCLM) Band 56 Heft 12

Abstract

Background:

Large burn injuries induce a systemic response in affected patients. Soluble ST2 (sST2) acts as a decoy receptor for interleukin-33 (IL-33) and has immunosuppressive effects. sST2 has been described previously as a prognostic serum marker. Our aim was to evaluate serum concentrations of sST2 and IL-33 after thermal injury and elucidate whether sST2 is associated with mortality in these patients.

Methods:

We included 32 burn patients (total body surface area [TBSA] >10%) admitted to our burn intensive care unit and compared them to eight healthy probands. Serum concentrations of sST2 and IL-33 were measured serially using an enzyme-linked immunosorbent assay (ELISA) technique.

Results:

The mean TBSA was 32.5%±19.6%. Six patients (18.8%) died during the hospital stay. Serum analyses showed significantly increased concentrations of sST2 and reduced concentrations of IL-33 in burn patients compared to healthy controls. In our study cohort, higher serum concentrations of sST2 were a strong independent predictor of mortality.

Conclusions:

Burn injuries cause an increment of sST2 serum concentrations with a concomitant reduction of IL-33. Higher concentrations of sST2 are associated with increased in-hospital mortality in burn patients.

Keywords: burn injury; burn trauma; interleukin-33; mortality; sST2; ST2
Corresponding author: Stefan Hacker, MD, FEBOPRAS, Division of Plastic and Reconstructive Surgery, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria

  1. Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

  2. Research funding: This study was partly financed by the Medical University of Vienna (research scholarship to TH), the Surgical Research Laboratory of the Medical University of Vienna, and the Ankersmit Laboratory for Cardiac and Thoracic Diagnosis & Regeneration.

  3. Employment or leadership: None declared.

  4. Honorarium: None declared.

  5. Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.

References

1. Brusselaers N, Monstrey S, Vogelaers D, Hoste E, Blot S. Severe burn injury in Europe: a systematic review of the incidence, etiology, morbidity, and mortality. Crit Care 2010;14:R188.10.1186/cc9300Suche in Google Scholar

2. Jeschke MG, Pinto R, Kraft R, Nathens AB, Finnerty CC, Gamelli RL, et al. Morbidity and survival probability in burn patients in modern burn care. Crit Care Med 2015;43:808–15.10.1097/CCM.0000000000000790Suche in Google Scholar

3. Hotchkiss RS, Coopersmith CM, McDunn JE, Ferguson TA. The sepsis seesaw: tilting toward immunosuppression. Nat Med 2009;15:496–7.10.1038/nm0509-496Suche in Google Scholar

4. Finnerty CC, Jeschke MG, Herndon DN, Gamelli R, Gibran N, Klein M, et al. Temporal cytokine profiles in severely burned patients: a comparison of adults and children. Mol Med 2008;14:553–60.10.2119/2007-00132.FinnertySuche in Google Scholar

5. Church D, Elsayed S, Reid O, Winston B, Lindsay R. Burn wound infections. Clin Microbiol Rev 2006;19:403–34.10.1128/CMR.19.2.403-434.2006Suche in Google Scholar

6. Hur J, Yang HT, Chun W, Kim JH, Shin SH, Kang HJ, et al. Inflammatory cytokines and their prognostic ability in cases of major burn injury. Ann Lab Med 2015;35:105–10.10.3343/alm.2015.35.1.105Suche in Google Scholar

7. Yeh FL, Lin WL, Shen HD, Fang RH. Changes in levels of serum IL-8 in burned patients. Burns 1997;23:555–9.10.1016/S0305-4179(97)00071-5Suche in Google Scholar

8. Vindenes HA, Ulvestad E, Bjerknes R. Concentrations of cytokines in plasma of patients with large burns: their relation to time after injury, burn size, inflammatory variables, infection, and outcome. Eur J Surg 1998;164:647–56.10.1080/110241598750005525Suche in Google Scholar PubMed

9. Csontos C, Foldi V, Palinkas L, Bogar L, Roth E, Weber G, et al. Time course of pro- and anti-inflammatory cytokine levels in patients with burns–prognostic value of interleukin-10. Burns 2010;36:483–94.10.1016/j.burns.2009.10.009Suche in Google Scholar PubMed

10. Kim HS, Kim JH, Yim H, Kim D. Changes in the levels of interleukins 6, 8, and 10, tumor necrosis factor alpha, and granulocyte-colony stimulating factor in Korean burn patients: relation to burn size and postburn time. Ann Lab Med 2012;32:339–44.10.3343/alm.2012.32.5.339Suche in Google Scholar PubMed PubMed Central

11. Yeh FL, Shen HD, Fang RH. Deficient transforming growth factor beta and interleukin-10 responses contribute to the septic death of burned patients. Burns 2002;28:631–7.10.1016/S0305-4179(02)00113-4Suche in Google Scholar

12. Finnerty CC, Herndon DN, Chinkes DL, Jeschke MG. Serum cytokine differences in severely burned children with and without sepsis. Shock 2007;27:4–9.10.1097/01.shk.0000235138.20775.36Suche in Google Scholar PubMed

13. Teodorczyk-Injeyan JA, Sparkes BG, Mills GB, Peters WJ, Falk RE. Impairment of T cell activation in burn patients: a possible mechanism of thermal injury-induced immunosuppression. Clin Exp Immunol 1986;65:570–81.Suche in Google Scholar

14. Liew FY, Pitman NI, McInnes IB. Disease-associated functions of IL-33: the new kid in the IL-1 family. Nat Rev Immunol 2010;10:103–10.10.1038/nri2692Suche in Google Scholar PubMed

15. Kakkar R, Lee RT. The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nat Rev Drug Discov 2008;7:827–40.10.1038/nrd2660Suche in Google Scholar PubMed PubMed Central

16. Liew FY, Girard JP, Turnquist HR. Interleukin-33 in health and disease. Nat Rev Immunol 2016;16:676–89.10.1038/nri.2016.95Suche in Google Scholar PubMed

17. Moussion C, Ortega N, Girard JP. The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel ‘alarmin’? PLoS One 2008;3:e3331.10.1371/journal.pone.0003331Suche in Google Scholar PubMed PubMed Central

18. Reichenbach DK, Schwarze V, Matta BM, Tkachev V, Lieberknecht E, Liu Q, et al. The IL-33/ST2 axis augments effector T-cell responses during acute GVHD. Blood 2015;125:3183–92.10.1182/blood-2014-10-606830Suche in Google Scholar PubMed PubMed Central

19. Alves-Filho JC, Sonego F, Souto FO, Freitas A, Verri WA, Jr., Auxiliadora-Martins M, et al. Interleukin-33 attenuates sepsis by enhancing neutrophil influx to the site of infection. Nat Med 2010;16:708–12.10.1038/nm.2156Suche in Google Scholar PubMed

20. Pascual-Figal DA, Januzzi JL. The biology of ST2: the International ST2 consensus panel. Am J Cardiol 2015;115:3B–7B.10.1016/j.amjcard.2015.01.034Suche in Google Scholar PubMed

21. Matta BM, Lott JM, Mathews LR, Liu Q, Rosborough BR, Blazar BR, et al. IL-33 is an unconventional Alarmin that stimulates IL-2 secretion by dendritic cells to selectively expand IL-33R/ST2+ regulatory T cells. J Immunol 2014;193:4010–20.10.4049/jimmunol.1400481Suche in Google Scholar PubMed PubMed Central

22. Zarpelon AC, Cunha TM, Alves-Filho JC, Pinto LG, Ferreira SH, McInnes IB, et al. IL-33/ST2 signalling contributes to carrageenin-induced innate inflammation and inflammatory pain: role of cytokines, endothelin-1 and prostaglandin E2. Br J Pharmacol 2013;169:90–101.10.1111/bph.12110Suche in Google Scholar PubMed PubMed Central

23. Mildner M, Storka A, Lichtenauer M, Mlitz V, Ghannadan M, Hoetzenecker K, et al. Primary sources and immunological prerequisites for sST2 secretion in humans. Cardiovasc Res 2010;87:769–77.10.1093/cvr/cvq104Suche in Google Scholar PubMed

24. Dieplinger B, Mueller T. Soluble ST2 in heart failure. Clin Chim Acta 2015;443:57–70.10.1016/j.cca.2014.09.021Suche in Google Scholar PubMed

25. Martinez-Rumayor A, Camargo CA, Green SM, Baggish AL, O’Donoghue M, Januzzi JL. Soluble ST2 plasma concentrations predict 1-year mortality in acutely dyspneic emergency department patients with pulmonary disease. Am J Clin Pathol 2008;130:578–84.10.1309/WMG2BFRC97MKKQKPSuche in Google Scholar PubMed

26. Hacker S, Lambers C, Pollreisz A, Hoetzenecker K, Lichtenauer M, Mangold A, et al. Increased soluble serum markers caspase-cleaved cytokeratin-18, histones, and ST2 indicate apoptotic turnover and chronic immune response in COPD. J Clin Lab Anal 2009;23:372–9.10.1002/jcla.20348Suche in Google Scholar PubMed PubMed Central

27. Oshikawa K, Kuroiwa K, Tago K, Iwahana H, Yanagisawa K, Ohno S, et al. Elevated soluble ST2 protein levels in sera of patients with asthma with an acute exacerbation. Am J Respir Crit Care Med 2001;164:277–81.10.1164/ajrccm.164.2.2008120Suche in Google Scholar PubMed

28. Kuroiwa K, Arai T, Okazaki H, Minota S, Tominaga S. Identification of human ST2 protein in the sera of patients with autoimmune diseases. Biochem Biophys Res Commun 2001;284:1104–8.10.1006/bbrc.2001.5090Suche in Google Scholar PubMed

29. Brunner M, Krenn C, Roth G, Moser B, Dworschak M, Jensen-Jarolim E, et al. Increased levels of soluble ST2 protein and IgG1 production in patients with sepsis and trauma. Intensive Care Med 2004;30:1468–73.10.1007/s00134-004-2184-xSuche in Google Scholar PubMed

30. Szerafin T, Niederpold T, Mangold A, Hoetzenecker K, Hacker S, Roth G, et al. Secretion of soluble ST2 – possible explanation for systemic immunosuppression after heart surgery. Thorac Cardiovasc Surg 2009;57:25–9.10.1055/s-2008-1039044Suche in Google Scholar PubMed

31. Dieplinger B, Egger M, Leitner I, Firlinger F, Poelz W, Lenz K, et al. Interleukin 6, galectin 3, growth differentiation factor 15, and soluble ST2 for mortality prediction in critically ill patients. J Crit Care 2016;34:38–45.10.1016/j.jcrc.2016.03.020Suche in Google Scholar PubMed

32. Mueller T, Dieplinger B, Gegenhuber A, Poelz W, Pacher R, Haltmayer M. Increased plasma concentrations of soluble ST2 are predictive for 1-year mortality in patients with acute destabilized heart failure. Clin Chem 2008;54:752–6.10.1373/clinchem.2007.096560Suche in Google Scholar PubMed

33. Dieplinger B, Egger M, Koehler W, Firlinger F, Poelz W, Lenz K, et al. Prognostic value of soluble ST2 in an unselected cohort of patients admitted to an intensive care unit – The Linz Intensive Care Unit (LICU) study. Clin Chim Acta 2012;413:587–93.10.1016/j.cca.2011.11.028Suche in Google Scholar PubMed

34. Krychtiuk KA, Stojkovic S, Lenz M, Brekalo M, Huber K, Wojta J, et al. Predictive value of low interleukin-33 in critically ill patients. Cytokine 2018;103:109–13.10.1016/j.cyto.2017.09.017Suche in Google Scholar PubMed

35. Haider T, Simader E, Hacker P, Ankersmit HJ, Heinz T, Hajdu S, et al. Increased serum concentrations of soluble ST2 are associated with pulmonary complications and mortality in polytraumatized patients. Clin Chem Lab Med 2018;56:810–7.10.1515/cclm-2017-0762Suche in Google Scholar PubMed

36. Dieplinger B, Januzzi JL, Jr., Steinmair M, Gabriel C, Poelz W, Haltmayer M, et al. Analytical and clinical evaluation of a novel high-sensitivity assay for measurement of soluble ST2 in human plasma – the Presage ST2 assay. Clin Chim Acta 2009;409: 33–40.10.1016/j.cca.2009.08.010Suche in Google Scholar PubMed

37. Mueller T, Dieplinger B. The Presage® ST2 Assay: analytical considerations and clinical applications for a high-sensitivity assay for measurement of soluble ST2. Expert Rev Mol Diagn 2013;13:13–30.10.1586/erm.12.128Suche in Google Scholar PubMed

38. Mueller T, Zimmermann M, Dieplinger B, Ankersmit HJ, Haltmayer M. Comparison of plasma concentrations of soluble ST2 measured by three different commercially available assays: the MBL ST2 assay, the Presage ST2 assay, and the R&D ST2 assay. Clin Chim Acta 2012;413:1493–4.10.1016/j.cca.2012.06.021Suche in Google Scholar PubMed

39. Mueller T, Dieplinger B. Soluble ST2 and galectin-3: what we know and don’t know analytically. EJIFCC 2016;27:224–37.Suche in Google Scholar

40. Shelhamer MC, Rowan MP, Cancio LC, Aden JK, Rhie RY, Merrill GA, et al. Elevations in inflammatory cytokines are associated with poor outcomes in mechanically ventilated burn patients. J Trauma Acute Care Surg 2015;79:431–6.10.1097/TA.0000000000000786Suche in Google Scholar PubMed

41. Mueller T, Jaffe AS. Soluble ST2–analytical considerations. Am J Cardiol 2015;115:8B–21B.10.1016/j.amjcard.2015.01.035Suche in Google Scholar PubMed

42. Lv R, Zhao J, Lei M, Xiao D, Yu Y, Xie J. IL-33 attenuates sepsis by inhibiting IL-17 receptor signaling through upregulation of SOCS3. Cell Physiol Biochem 2017;42:1961–72.10.1159/000479836Suche in Google Scholar PubMed

43. Lan F, Yuan B, Liu T, Luo X, Huang P, Liu Y, et al. Interleukin-33 facilitates neutrophil recruitment and bacterial clearance in S. aureus-caused peritonitis. Mol Immunol 2016;72:74–80.10.1016/j.molimm.2016.03.004Suche in Google Scholar PubMed

44. Evers LH, Bhavsar D, Mailander P. The biology of burn injury. Exp Dermatol 2010;19:777–83.10.1111/j.1600-0625.2010.01105.xSuche in Google Scholar PubMed

45. Al-Ghoul WM, Khan M, Fazal N, Sayeed MM. Mechanisms of postburn intestinal barrier dysfunction in the rat: roles of epithelial cell renewal, E-cadherin, and neutrophil extravasation. Crit Care Med 2004;32:1730–9.10.1097/01.CCM.0000132896.62368.01Suche in Google Scholar

46. Hoogerwerf JJ, Tanck MW, van Zoelen MA, Wittebole X, Laterre PF, van der Poll T. Soluble ST2 plasma concentrations predict mortality in severe sepsis. Intensive Care Med 2010;36:630–7.10.1007/s00134-010-1773-0Suche in Google Scholar PubMed PubMed Central

47. Jenkins WS, Roger VL, Jaffe AS, Weston SA, AbouEzzeddine OF, Jiang R, et al. Prognostic value of soluble ST2 after myocardial infarction: a community perspective. Am J Med 2017; 130:1112.e9–15.10.1016/j.amjmed.2017.02.034Suche in Google Scholar PubMed PubMed Central

Received: 2018-01-11
Accepted: 2018-05-24
Published Online: 2018-06-27
Published in Print: 2018-11-27

©2018 Walter de Gruyter GmbH, Berlin/Boston

Artikel in diesem Heft

  1. Frontmatter
  2. Editorial
  3. Observing an analyzer’s operational life cycle: a useful management tool for clinical laboratories
  4. Reviews
  5. Personalized laboratory medicine: a patient-centered future approach
  6. Circular RNAs: a new class of biomarkers as a rising interest in laboratory medicine
  7. Mini Review
  8. Impact of interactions between drugs and laboratory test results on diagnostic test interpretation – a systematic review
  9. Opinion Paper
  10. Uncertainty in measurement and total error: different roads to the same quality destination?
  11. Guidelines and Recommendations
  12. Joint EFLM-COLABIOCLI Recommendation for venous blood sampling
  13. General Clinical Chemistry and Laboratory Medicine
  14. Evidence for the positive impact of ISO 9001 and ISO 15189 quality systems on laboratory performance – evaluation of immunohaematology external quality assessment results during 19 years in Austria
  15. Effects of high-dose, intravenous lipid emulsion on laboratory tests in humans: a randomized, placebo-controlled, double-blind, clinical crossover trial
  16. Commutability of the certified reference materials for the standardization of β-amyloid 1-42 assay in human cerebrospinal fluid: lessons for tau and β-amyloid 1-40 measurements
  17. Failure rate prediction of equipment: can Weibull distribution be applied to automated hematology analyzers?
  18. Evaluation of serum alkaline phosphatase measurement through the 4-year trueness verification program in China
  19. Increased serum concentrations of soluble ST2 predict mortality after burn injury
  20. The clinical significance of borderline results of the Elia CTD Screen assay
  21. Reference Values and Biological Variations
  22. Reference intervals for 33 biochemical analytes in healthy Indian population: C-RIDL IFCC initiative
  23. Cancer Diagnostics
  24. BCL2L12 improves risk stratification and prediction of BFM-chemotherapy response in childhood acute lymphoblastic leukemia
  25. Cardiovascular Diseases
  26. The correlation between glucose fluctuation from self-monitored blood glucose and the major adverse cardiac events in diabetic patients with acute coronary syndrome during a 6-month follow-up by WeChat application
  27. Diabetes
  28. Impact of blood cell counts and volumes on glucose concentration in uncentrifuged serum and lithium-heparin blood tubes
  29. Letters to the Editor
  30. Standard process-oriented workflow introduces pre-analytical error when used in large study sample batches
  31. Comparison of three staining methods in the automated digital cell imaging analyzer Sysmex DI-60
  32. Detection of Plasmodium falciparum using automated digital cell morphology analyzer Sysmex DI-60
  33. Serum ischemia-modified albumin concentration may reflect long-term hypoxia in chronic respiratory disease: a pilot study
  34. Wet absorptive microsampling at home for HbA1c monitoring in diabetic children
  35. Serum endocan levels in patients with chronic obstructive pulmonary disease: a potential role in the evaluation of susceptibility to exacerbation
  36. Analytical and clinical validation of the new Roche Elecsys Vitamin D Total II assay
  37. Analytical validation of two second generation thyroglobulin immunoassays (Roche and Thermo Fisher)
  38. Omission of preservatives during 24-h of urine collection for the analysis of fractionated metanephrines enhance patient convenience
  39. Transient monoclonal gammopathy in a 2-year-old child with combined viral and bacterial infection
  40. Nephelometric assay of urine free light chains: an alternative and early clinical test for Bence-Jones protein quantification
  41. Congress Abstracts
  42. Congress of Laboratory Medicine and Clinical Chemistry 7th Annual Meeting of the Austrian Society for Laboratory Medicine and Clinical Chemistry (ÖGLMKC)
  43. 50th National Congress of the Italian Society of Clinical Biochemistry and Clinical Molecular Biology (SIBioC – Laboratory Medicine)
  44. Revolution drives Evolution – from measuring to understanding: Annual meeting of Swiss Society of Clinical Chemistry (SSCC) in Bern, November 15-16 2018
https://doi.org/10.1515/cclm-2018-0042
Schlagwörter für diesen Artikel
burn injury; burn trauma; interleukin-33; mortality; sST2; ST2

Artikel in diesem Heft

  1. Frontmatter
  2. Editorial
  3. Observing an analyzer’s operational life cycle: a useful management tool for clinical laboratories
  4. Reviews
  5. Personalized laboratory medicine: a patient-centered future approach
  6. Circular RNAs: a new class of biomarkers as a rising interest in laboratory medicine
  7. Mini Review
  8. Impact of interactions between drugs and laboratory test results on diagnostic test interpretation – a systematic review
  9. Opinion Paper
  10. Uncertainty in measurement and total error: different roads to the same quality destination?
  11. Guidelines and Recommendations
  12. Joint EFLM-COLABIOCLI Recommendation for venous blood sampling
  13. General Clinical Chemistry and Laboratory Medicine
  14. Evidence for the positive impact of ISO 9001 and ISO 15189 quality systems on laboratory performance – evaluation of immunohaematology external quality assessment results during 19 years in Austria
  15. Effects of high-dose, intravenous lipid emulsion on laboratory tests in humans: a randomized, placebo-controlled, double-blind, clinical crossover trial
  16. Commutability of the certified reference materials for the standardization of β-amyloid 1-42 assay in human cerebrospinal fluid: lessons for tau and β-amyloid 1-40 measurements
  17. Failure rate prediction of equipment: can Weibull distribution be applied to automated hematology analyzers?
  18. Evaluation of serum alkaline phosphatase measurement through the 4-year trueness verification program in China
  19. Increased serum concentrations of soluble ST2 predict mortality after burn injury
  20. The clinical significance of borderline results of the Elia CTD Screen assay
  21. Reference Values and Biological Variations
  22. Reference intervals for 33 biochemical analytes in healthy Indian population: C-RIDL IFCC initiative
  23. Cancer Diagnostics
  24. BCL2L12 improves risk stratification and prediction of BFM-chemotherapy response in childhood acute lymphoblastic leukemia
  25. Cardiovascular Diseases
  26. The correlation between glucose fluctuation from self-monitored blood glucose and the major adverse cardiac events in diabetic patients with acute coronary syndrome during a 6-month follow-up by WeChat application
  27. Diabetes
  28. Impact of blood cell counts and volumes on glucose concentration in uncentrifuged serum and lithium-heparin blood tubes
  29. Letters to the Editor
  30. Standard process-oriented workflow introduces pre-analytical error when used in large study sample batches
  31. Comparison of three staining methods in the automated digital cell imaging analyzer Sysmex DI-60
  32. Detection of Plasmodium falciparum using automated digital cell morphology analyzer Sysmex DI-60
  33. Serum ischemia-modified albumin concentration may reflect long-term hypoxia in chronic respiratory disease: a pilot study
  34. Wet absorptive microsampling at home for HbA1c monitoring in diabetic children
  35. Serum endocan levels in patients with chronic obstructive pulmonary disease: a potential role in the evaluation of susceptibility to exacerbation
  36. Analytical and clinical validation of the new Roche Elecsys Vitamin D Total II assay
  37. Analytical validation of two second generation thyroglobulin immunoassays (Roche and Thermo Fisher)
  38. Omission of preservatives during 24-h of urine collection for the analysis of fractionated metanephrines enhance patient convenience
  39. Transient monoclonal gammopathy in a 2-year-old child with combined viral and bacterial infection
  40. Nephelometric assay of urine free light chains: an alternative and early clinical test for Bence-Jones protein quantification
  41. Congress Abstracts
  42. Congress of Laboratory Medicine and Clinical Chemistry 7th Annual Meeting of the Austrian Society for Laboratory Medicine and Clinical Chemistry (ÖGLMKC)
  43. 50th National Congress of the Italian Society of Clinical Biochemistry and Clinical Molecular Biology (SIBioC – Laboratory Medicine)
  44. Revolution drives Evolution – from measuring to understanding: Annual meeting of Swiss Society of Clinical Chemistry (SSCC) in Bern, November 15-16 2018
Jetzt anmelden und 20% sparen
Institutioneller Zugang
Wie funktioniert Authentifizierung?
Haben Sie eine Idee, wie wir unsere Website verbessern können?
Bitte schreiben Sie uns.
© 2025 De Gruyter Brill
Heruntergeladen am 6.9.2025 von https://www.degruyterbrill.com/document/doi/10.1515/cclm-2018-0042/html
Button zum nach oben scrollen